Tseng, Ssu-Hsueh Cheng, Max A Farmer, Emily Ferrall, Louise Kung, Yu Jui Lam, Brandon Lim, Ling Wu, T-C Hung, Chien-Fu
Published in
Journal for immunotherapy of cancer
Type I interferons (IFN) promote dendritic cells maturation and subsequently enhance generation of antigen-specific CD8 +T cell for the control of tumor. Using type I interferons as an adjuvant to vaccination could prove to be a potent strategy. However, type I interferons have a short half-life. Albumin linked to a protein will prolong the half-li...
Levy, Gabriel Guglielmelli, Paola Langmuir, Peter Constantinescu, Stefan
Published in
Journal for immunotherapy of cancer
During SARS-CoV-2 infection, the innate immune response can be inhibited or delayed, and the subsequent persistent viral replication can induce emergency signals that may culminate in a cytokine storm contributing to the severe evolution of COVID-19. Cytokines are key regulators of the immune response and virus clearance, and, as such, are linked t...
Nguyen, Lee S Bretagne, Marie Arrondeau, Jennifer Zahr, Noel Ederhy, Stephane Abbar, Baptiste Pinna, Bruno Allenbach, Yves Mira, Jean-Paul Moslehi, Javid
...
Published in
Journal for immunotherapy of cancer
Immune-checkpoint inhibitors (ICI) have revolutionized cancer therapy but are associated with infrequent but lethal myocarditis, for which management remains uncertain. Abatacept, a CTLA-4 fusion protein targeting CD86 on antigen presenting cells and leading to global T-cell anergy, has been described as a potential treatment in individual reports....
Shinohara, Shuichi Takahashi, Yusuke Komuro, Hiroyasu Matsui, Takuya Sugita, Yusuke Demachi-Okamura, Ayako Muraoka, Daisuke Takahara, Hirotomo Nakada, Takeo Sakakura, Noriaki
...
Published in
Journal for immunotherapy of cancer
A better understanding of the tumor immune microenvironment (TIME) will facilitate the development of prognostic biomarkers and more effective therapeutic strategies in patients with lung cancer. However, little has been reported on the comprehensive evaluation of complex interactions among cancer cells, immune cells, and local immunosuppressive el...
Zucali, Paolo Andrea Lin, Chia-Chi Carthon, Bradley C Bauer, Todd M Tucci, Marcello Italiano, Antoine Iacovelli, Roberto Su, Wu-Chou Massard, Christophe Saleh, Mansoor
...
Published in
Journal for immunotherapy of cancer
Preclinical data suggest that concurrent treatment of anti-CD38 and antiprogrammed death 1 (PD-1)/programmed death ligand 1 (PD-L1) antibodies substantially reduce primary tumor growth by reversing T-cell exhaustion and thus enhancing anti-PD-1/PD-L1 efficacy. This phase I/II study enrolled patients with metastatic castration-resistant prostate can...
Zhou, Liye Zeng, Zexian Egloff, Ann Marie Zhang, Fan Guo, Fei Campbell, Katie M Du, Peter Fu, Jingxin Zolkind, Paul Ma, Xiaojing
...
Published in
Journal for immunotherapy of cancer
Immune checkpoint blockade (ICB) response in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) is limited to 15%-20% of patients and underpinnings of resistance remain undefined. Starting with an anti-PD1 sensitive murine HNSCC cell line, we generated an isogenic anti-PD1 resistant model. Mass cytometry was used to delineate tumor ...
Jing, Ying Chen, Xue Li, Kunyan Liu, Yaoming Zhang, Zhao Chen, Yiqing Liu, Yuan Wang, Yushu Lin, Steven H Diao, Lixia
...
Published in
Journal for immunotherapy of cancer
To determine whether antibiotic treatment is a risk factor for immune-related adverse events (irAEs) across different patients with cancer receiving anti-PD-1/PD-L1 therapies. The retrospective analysis includes clinical information from 767 patients with cancer treated at Hunan Cancer Hospital from 2017 to 2020. The pharmacovigilance data analysis...
Semmrich, Monika Marchand, Jean-Baptiste Fend, Laetitia Rehn, Matilda Remy, Christelle Holmkvist, Petra Silvestre, Nathalie Svensson, Carolin Kleinpeter, Patricia Deforges, Jules
...
Published in
Journal for immunotherapy of cancer
Immune checkpoint blockade (ICB) is a clinically proven concept to treat cancer. Still, a majority of patients with cancer including those with poorly immune infiltrated 'cold' tumors are resistant to currently available ICB therapies. Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is one of few clinically validated targets for ICB, but toxic...
Merchant, Rosemina Galligan, Carole Munegowda, Manjunatha Ankathatti Pearce, L Bruce Lloyd, Peter Smith, Paul Merchant, Fahar To, Minh D
Published in
Journal for immunotherapy of cancer
Recombinant human interleukin-2 (rhIL-2, aldesleukin) is Food and Drug Administration approved for the treatment of metastatic melanoma and renal cell carcinoma and has achieved durable response in a subset of patients. However, its utility as an immunotherapeutic drug is limited by undesirable activation of immune suppressive regulatory T cells (T...
Gonugunta, Amrit S von Itzstein, Mitchell S Mu-Mosley, Hong Fattah, Farjana Farrar, J David Mobely, Angela Rashdan, Sawsan Lai, Sunny Bhai, Salman F Bermas, Bonnie L
...
Published in
Journal for immunotherapy of cancer
Immune-related adverse events (irAE) may affect almost any organ system and occur at any point during treatment with immune checkpoint inhibitors (ICI). We present a patient with advanced lung cancer receiving antiprogrammed death 1 checkpoint inhibitor who developed a delayed-onset visual irAE treated with corticosteroids. Through assessment of lo...
